While a promising strategy, LUNAR, a phase III placebo-controlled trial using rituximab as an add-on therapy, did not achieve its primary endpoints of a complete or partial renal response at 52 weeks (Rovin et al, Arthritis Rheum 2012)
51 : 11631168 Rights and permissions About this article Cite this article Pettegrew, J., Levine, J
Data reported by Liu K
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
Cell 57 , 21272139.e6 (2022)
For one thing, as effective as they are, these drugs behave more like statins than antibiotics: They work while you take them